Cerebrospinal fluid tumor markers for the diagnosis and management of leptomeningeal metastases
- 31 January 1987
- journal article
- editorial
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 23 (1) , 1-4
- https://doi.org/10.1016/0277-5379(87)90410-x
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Detection of central nervous system metastasis with cerebrospinal fluid beta-2-microglobulinCancer, 2006
- Cerebrospinal fluid beta2-microglobulin: a study in controls and patients with metastatic and non-metastatic neurological diseasesEuropean Journal of Cancer and Clinical Oncology, 1986
- Cerebrospinal fluid polyamines: Biochemical markers of malignant childhood brain tumorsAnnals of Neurology, 1986
- Unreliability of β-2-microglobulin in early detection of central nervous system relapse in acute lymphoblastic leukemiaEuropean Journal of Cancer and Clinical Oncology, 1985
- Assay for β-Glucuronidase in Cerebrospinal Fluid: Usefulness for the Detection of Neoplastic MeningitisMayo Clinic Proceedings, 1985
- Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patientsCancer, 1982
- Lactic dehydrogenase isoenzymes in the cerebrospinal fluid of patients with systemic cancerCancer, 1981
- Cerebrospinal fluid biochemical markers of central nervous system metastasesAnnals of Neurology, 1980
- Diagnosis of Leukemia or Lymphoma in the Central Nervous System by Beta2-Microglobulin DeterminationNew England Journal of Medicine, 1980
- The β2-microglobulin content of the cerebrospinal fluid in neurological diseaseJournal of the Neurological Sciences, 1977